Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma

Trial Profile

Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma

Discontinued
Phase of Trial: Phase I

Latest Information Update: 08 Jul 2017

At a glance

  • Drugs Sirolimus (Primary) ; Cyclophosphamide; Cytarabine; Cytarabine; Dexamethasone; Dexamethasone; Mercaptopurine; Methotrexate; Mitoxantrone; Pegaspargase; Vincristine
  • Indications Acute lymphoblastic leukaemia; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 22 Jun 2016 Status changed from recruiting to discontinued.
    • 28 Jun 2013 Planned End Date changed from 1 Mar 2017 to 1 Apr 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top